TFX Teleflex Incorporated

Teleflex to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Teleflex to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

WAYNE, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Jake Elguicze, Treasurer and Vice President of Investor Relations, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 24, 2021 at 9:15am (ET).

A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor portion of the Teleflex website at .

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

Source:

Teleflex Incorporated

Jake Elguicze

Treasurer and Vice President, Investor Relations

610-948-2836



EN
10/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex Announces Multiple Clinical and Real-World Evidence Studies t...

Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) -Additional studies examine post-surgery medication use, rates of hospitalization and adverse events of standard BPH treatments -Teleflex unveils latest advancements in BPH treatment with UroLift™ 2 System with Advanced Tissue Control (ATC) designed to treat all prostate types -...

 PRESS RELEASE

Teleflex Announces the Limited Market Release of the Wattson™ Temporar...

Teleflex Announces the Limited Market Release of the Wattson™ Temporary Pacing Guidewire Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire intended to introduce and position catheters and other interventional devices within the chambers of the heart while transmitting an electrical signal from an external pulse generator to the heart WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the Wattson™ Temporary Pacing Gui...

 PRESS RELEASE

Teleflex to Present at the BofA Securities 2024 Health Care Conference

Teleflex to Present at the BofA Securities 2024 Health Care Conference WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 14, 2024, at 2:20 p.m. (PT). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at . About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and ...

 PRESS RELEASE

Teleflex Announces First Quarter 2024 Earnings Conference Call Informa...

Teleflex Announces First Quarter 2024 Earnings Conference Call Information WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024. To participate in the conference call, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, . An audio replay of the call will be available beginning at 11:00 am Easte...

 PRESS RELEASE

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced T...

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has rece...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch